Detalles de la búsqueda
1.
Long-term open-label safety study of galcanezumab in patients with episodic or chronic cluster headache.
Cephalalgia
; 42(11-12): 1225-1235, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35633025
2.
Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies.
BMC Neurol
; 20(1): 25, 2020 Jan 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-31952501
3.
Correction to: Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies.
BMC Neurol
; 20(1): 90, 2020 03 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-32169042
4.
A cohort study of the risk of seizures in a pediatric population treated with atomoxetine or stimulant medications.
Pharmacoepidemiol Drug Saf
; 22(4): 386-93, 2013 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-23280590
5.
Atomoxetine and cerebrovascular outcomes in adults.
J Clin Psychopharmacol
; 29(5): 453-60, 2009 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-19745645
6.
Hepatic events associated with atomoxetine treatment for attention-deficit hyperactivity disorder.
Drug Saf
; 31(4): 345-54, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-18366245
7.
Meta-analysis of suicide-related behavior events in patients treated with atomoxetine.
J Am Acad Child Adolesc Psychiatry
; 47(2): 209-218, 2008 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-18176331
8.
Meta-analysis of aggression or hostility events in randomized, controlled clinical trials of atomoxetine for ADHD.
Biol Psychiatry
; 61(5): 713-9, 2007 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-16996485
9.
Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
Clin Ther
; 29(6): 1168-77, 2007 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-17692731
10.
Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression.
J Child Adolesc Psychopharmacol
; 17(4): 407-20, 2007 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-17822337
11.
Acute and longer-term safety results from a pooled analysis of duloxetine studies for the treatment of children and adolescents with major depressive disorder.
J Child Adolesc Psychopharmacol
; 25(4): 293-305, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25978741
12.
Meta-analysis of suicide-related behavior or ideation in child, adolescent, and adult patients treated with atomoxetine.
J Child Adolesc Psychopharmacol
; 24(8): 426-34, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-25019647
13.
A double-blind efficacy and safety study of duloxetine fixed doses in children and adolescents with major depressive disorder.
J Child Adolesc Psychopharmacol
; 24(4): 170-9, 2014 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-24815533
14.
A double-blind efficacy and safety study of duloxetine flexible dosing in children and adolescents with major depressive disorder.
J Child Adolesc Psychopharmacol
; 24(4): 180-9, 2014 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-24813026
15.
Prospective assessment of suicidal ideation and behavior: an internet survey of pharmaceutical sponsor practices.
Innov Clin Neurosci
; 11(9-10): 14-22, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-25520885
16.
Assessment of falls in older patients treated with duloxetine: a secondary analysis of a 24-week randomized, placebo-controlled trial.
Prim Care Companion CNS Disord
; 15(1)2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23724353
17.
The risk of bleeding with duloxetine treatment in patients who use nonsteroidal anti-inflammatory drugs (NSAIDs): analysis of placebo-controlled trials and post-marketing adverse event reports.
Drug Healthc Patient Saf
; 5: 211-9, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-24348072
18.
Effect of atomoxetine on Tanner stage sexual development in children and adolescents with attention deficit/hyperactivity disorder: 18-month results from a double-blind, placebo-controlled trial.
Curr Med Res Opin
; 27 Suppl 2: 45-52, 2011.
Artículo
en Inglés
| MEDLINE | ID: mdl-21973230
19.
Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder.
Pediatrics
; 121(2): e314-20, 2008 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-18245404
20.
Seizure risk in patients with attention-deficit-hyperactivity disorder treated with atomoxetine.
Dev Med Child Neurol
; 49(7): 498-502, 2007 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-17593120